In this week’s episode of the Xtalks Life Science Podcast, host Ayesha Rashid, Senior Life Science Journalist at Xtalks, spoke with Peter Vanderklish, PhD, chief scientific officer at Spinogenix, a company developing therapeutics aimed at restoring synaptic connections for conditions such as ALS, Alzheimer’s disease, schizophrenia and Fragile X syndrome. Dr. Vanderklish’s decades of research, from his graduate work at UC Irvine to his roles at The Scripps Research Institute and UC Irvine, have helped shape our understanding of synaptic function, including post-synaptic long-term potentiation (LTP) mechanisms and the role of integrins in stabilizing synaptic structure. His more recent work focuses on dendritic spine abnormalities in Fragile X syndrome and how these changes relate to chronic anxiety and social avoidance behaviors. Dr. Vanderklish is an Associate Professor in Neuroscience at The Scripps Research Institute and a Visiting Professor in Anatomy and Neurobiology at UC Irvine. Tune in to learn how Spinogenix is advancing novel therapies designed to rebuild synapses and transform treatment for neurological diseases. For more life science and medical device content, visit the Xtalks Vitals homepage. https://xtalks.com/vitals/ Follow Us on Social Media Twitter: https://twitter.com/XtalksInstagram: https://www.instagram.com/xtalks/Facebook: https://www.facebook.com/Xtalks.Webinars/LinkedIn: https://www.linkedin.com/company/xtalks-webconferencesYouTube: https://www.youtube.com/c/XtalksWebinars/featured